Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - Audentes Therapeutics, Inc. | bold-ex992_6.htm |
| EX-99.1 - EX-99.1 - Audentes Therapeutics, Inc. | bold-ex991_7.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 16, 2018
AUDENTES THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
|
|
001-37833 |
|
46-1606174 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
600 California Street, 17th Floor San Francisco, California |
|
94108 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(415) 818-1001
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On May 16, 2018, Audentes Therapeutics, Inc. (the “Company”) issued a press release attached hereto as Exhibit 99.1 announcing interim data from the first dose cohort of ASPIRO, its Phase 1/2 clinical trial. In addition, the Company plans to present the information in the investor presentation attached hereto as Exhibit 99.2 at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held in Chicago, IL on May 16, 2018.
Item 9.01Financial Statements and Exhibits.
|
Exhibit |
|
|
|
Number |
|
Description |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
AUDENTES THERAPEUTICS, INC. |
||
|
|
|
|
|
By: |
|
/s/ Thomas Soloway |
|
|
|
Thomas Soloway |
|
|
|
Chief Financial Officer |
Date: May 16, 2018